罗斯布里亚Hominis在饮食诱导的肥胖症中改善宿主代谢
Wenli Huang1,2,3, Wenyi Zhu1,2,3, Yu Lin1,2,3
1Microbiota I-Center (MagIC), Hong Kong, China.
Gut microbes
|February 20, 2025
概括
一种新的益生菌Roseburia hominis显示出治疗肥胖和代谢障碍的潜力. 在小鼠中补充预防体重增加,改善新陈代谢,减少脂肪肝,突出其治疗前景.
科学领域:
- 微生物学 微生物学
- 代谢性疾病研究研究.
- 肠道微生物组研究的研究
背景情况:
- 肥胖和代谢性疾病对全球健康构成重大挑战.
- 活生物疗法代表了新型治疗策略的有希望的途径.
- 肠道微生物群失调越来越多地与代谢功能障碍有关.
研究的目的:
- 为了识别和描述肥胖和代谢疾病治疗的新型益生菌候选人.
- 为了研究益生菌候选人Roseburia hominis的抗肥胖作用.
- 阐明罗兹布里亚人类的治疗作用背后的机制.
主要方法:
- 对肥胖者与瘦身者肠道微生物群的比较分析.
- 在体内研究使用高脂肪饮食诱导的肥胖小鼠模型.
- 评估体重,葡萄糖和脂质代谢以及脂肪组织特征.
- 对微生物代谢物产生和关键信号通路 (Sirtuin1/mTOR) 的分析.
主要成果:
- 发现Roseburia hominis在肥胖人群中被耗尽,与BMI和甘油三酸有负相关.
- 在小鼠中,R. hominis补充剂可以预防体重增加,代谢障碍和脂肪肝.
- 益生菌抑制了白色脂肪组织的扩张和棕色脂肪组织的白化.
- 这些效应部分由尼古丁胺 рибоoside 生产和 Sirtuin1/mTOR 途径激活介导.
结论:
- 在临床前模型中,Roseburia hominis显示出显著的抗肥胖和代谢益处.
- 这种细菌代表了下一代活生物治疗的有希望的候选者.
- 用Roseburia hominis针对肠道微生物组提供了一种用于管理肥胖和代谢疾病的新策略.
相关概念视频
01:19Regulation of Metabolism
Cellular needs and conditions vary from cell to cell and change within individual cells over time. For example, the required enzymes and energetic demands of stomach cells are different from those of fat storage cells, skin cells, blood cells, and nerve cells. Furthermore, a digestive cell works much harder to process and break down nutrients during the time that closely follows a meal compared with many hours after a meal. As these cellular demands and conditions vary, so do the amounts and...
01:24Obesity
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...